Thalidomide-NH-C2-PEG3-OH is primarily utilized in the development of PROTACs (Proteolysis Targeting Chimeras), a cutting-edge technology in drug discovery. Its structure enables the recruitment of E3 ubiquitin ligases to target proteins, facilitating their degradation via the ubiquitin-proteasome system. This approach is particularly valuable in targeting proteins that are traditionally considered "undruggable," such as transcription factors or scaffold proteins. The compound's PEG3 linker enhances solubility and bioavailability, making it suitable for in vitro and in vivo studies. It is widely applied in cancer research, neurodegenerative disease studies, and the development of novel therapeutic strategies for challenging diseases.